RXi Pharmaceuticals in Marlborough has completed enrollment in a second phase of a clinical trial of an ointment meant to treat cutaneous warts by activating the body’s immune system to fight the wart.
The ointment, marketed as Samcyprone, includes the small molecule diphenylcyclopropenone that initiates a T-cell response to help fight the infection, the company said in a press release Wednesday.
RXi acquired the license to Symcyprone in 2015.
The second phase of multi-center, multi-dose trial includes subjects with at least one cutaneous, plantar or periungual wart present for at least four weeks.
According to the company, existing wart treatments can be unsuccessful, time consuming and warts can reappear.
“It is well established that cell-mediated immune response plays a significant role in controlling (human papillomaviruses that cause the warts),” the company said.
